Share Price | Universe Pharmaceuticals, Inc. Stock Analysis & Recommendation

Q: What does Universe Pharmaceuticals, Inc. do?

Overview: Universe Pharmaceuticals, Inc. operates in the Pharmaceuticals & Biotechnology industry and is categorized as a micro-cap company.Financial Snapshot: Most recent Net Sales: 19 Million (Quarterly Results - Jun 2012) Most recent Net Profit: -77 Million (Quarterly Results - Jun 2012) Market-cap: USD 2.24 Million (Micro Cap)Key Metrics: P/E: NA (Loss Making) Industry P/E: NA Dividend Yield: 0.00% Debt Equity: -0.47 Return on Equity: -999,999.00% Price to Book: 0.05Contact Details: Details: No Company Details Available Registrar Address: Not available.

Q: Is Universe Pharmaceuticals, Inc. technically bullish or bearish?

As of 11 September 2025, the technical trend for Universe Pharmaceuticals, Inc. has changed from mildly bearish to sideways. The current stance is neutral, with mixed signals across different indicators. The weekly MACD is mildly bullish, while the monthly MACD is also mildly bullish. The RSI shows no signal on the weekly timeframe but is bullish on the monthly. Bollinger Bands indicate a bullish trend weekly but are mildly bearish monthly. Daily moving averages are mildly bearish, and the KST shows a mildly bullish weekly trend but bearish monthly. Dow Theory indicates no trend in both weekly and monthly perspectives, while the OBV is bullish monthly.In terms of performance, the stock has outperformed the S&P 500 over the past week and month, with returns of 1.72% and 21.4%, respectively, compared to 1.05% and 2.33% for the index. However, the year-to-date and one-year returns are significantly negative at -82.99% and -98.06%, respectively, contrasting sharply with the S&P 500's positive returns.

Price Point

High/Low

1Day

52 Week

Valuation

Technical

Day's Volume

CASH

31.3 k

Shareholding (Mar 2025)

FII

0.04%

Held by 2 FIIs

DII

99.96%

Held by 0 DIIs

Promoter

0.00%

How big is Universe Pharmaceuticals, Inc.?

22-Jun-2025

As of Jun 18, Universe Pharmaceuticals, Inc. has a market capitalization of 2.24 million and reported net sales of 162.49 million with a net profit loss of 315.54 million for the latest four quarters. The balance sheet as of Sep 24 shows shareholder's funds of 45.50 million and total assets of 67.95 million.

View full answer

What does Universe Pharmaceuticals, Inc. do?

22-Jun-2025

Universe Pharmaceuticals, Inc. is a micro-cap company in the Pharmaceuticals & Biotechnology industry, reporting net sales of $19 million and a net loss of $77 million as of June 2012. The company has a market cap of $2.24 million and no dividend yield.

View full answer

Is Universe Pharmaceuticals, Inc. technically bullish or bearish?

20-Sep-2025

As of September 11, 2025, Universe Pharmaceuticals, Inc. shows a neutral trend with mixed signals, mildly bullish indicators on weekly and monthly MACD, while outperforming the S&P 500 recently, but has significantly negative year-to-date and one-year returns.

View full answer

Compare Universe Pharmaceuticals, Inc. with Similar Stocks

ZyVersa Therapeutics, Inc.Artelo Biosciences, Inc.Kiora Pharmaceuticals, Inc.

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.Unlock 29 Markets

Dashboard

Unrated Stock - No Analysis Available

Mojo Parameters

Stock DNA

Industry

Pharmaceuticals & Biotechnology

Market cap

USD 1 Million ()

P/E

NA (Loss Making)

Industry P/E

Dividend Yield

0.00%

Debt Equity

-0.72

Return on Equity

-999,999.00%

Price to Book

0.01

Revenue and Profits:

Net Sales:

19 Million

(Quarterly Results - Jun 2012)

Net Profit:

-77 Million

Total Returns

Total Returns (Price + Dividend)

TimePeriod

Price Return

Dividend Return

Total Return

3 Months

-6.79%

6 Months

8.45%

1 Year

-63.13%

2 Years

-99.72%

3 Years

368.24%

4 Years

-99.93%

5 Years

0.0%

Universe Pharmaceuticals, Inc. for the last several years.

Risk Adjusted Returns v/s

News & Corporate Actions

News

No Recent News for the Company

Announcements

No announcement available

Corporate Actions

No corporate action available

Key Factors

Quality key factors

Factor

Value

Sales Growth (5y)

-13.58%

EBIT Growth (5y)

-6.56%

EBIT to Interest (avg)

-0.01

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

-0.72

Sales to Capital Employed (avg)

3.18

Tax Ratio

3.15%

Dividend Payout Ratio

Pledged Shares

Institutional Holding

8.31%

ROCE (avg)

ROE (avg)

Valuation key factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

0.05

EV to EBIT

-0.49

EV to EBITDA

-0.36

EV to Capital Employed

-0.80

EV to Sales

-0.12

PEG Ratio

Dividend Yield

ROCE (Latest)

Negative Capital Employed

ROE (Latest)

-1055.87%

Technicals key factors

Indicator

Weekly

Monthly

MACD

Mildly Bullish

RSI

No Signal

Bullish

Bollinger Bands

Bearish

Moving Averages

Bearish (Daily)

KST

Mildly Bearish

Bearish

Dow Theory

No Trend

Mildly Bearish

OBV

Bullish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Shareholding

Shareholding Snapshot : Mar 2025

Shareholding Compare (%holding)

Majority shareholders

Foreign Institutions

Domestic Funds

Held in 0 Schemes (0%)

Foreign Institutions

Held by 2 Foreign Institutions (0.04%)

Strategic Entities with highest holding

Highest Public shareholder

Financial

[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'12 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Jun 2012 is -78.17% vs 15.13% in Jun 2011",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Jun 2012 is -155.63% vs -308.11% in Jun 2011",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Jun'12",
        "Jun'11",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "19.10",
          "val2": "87.50",
          "chgp": "-78.17%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-10.40",
          "val2": "-66.70",
          "chgp": "84.41%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "10.90",
          "val2": "18.80",
          "chgp": "-42.02%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "27.50",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-77.20",
          "val2": "-30.20",
          "chgp": "-155.63%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Sep'23",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Sep 2023 is -19.45% vs -16.46% in Sep 2022",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Sep 2023 is 28.74% vs -176.99% in Sep 2022",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Sep'23",
        "Sep'22",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "32.30",
          "val2": "40.10",
          "chgp": "-19.45%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-3.00",
          "val2": "-6.90",
          "chgp": "56.52%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.20",
          "val2": "0.20",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-6.20",
          "val2": "-8.70",
          "chgp": "28.74%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-109.20%",
          "val2": "-185.30%",
          "chgp": "7.61%",
          "chgp_class": "positive"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Jun'12 - YoY

Jun'12

Jun'11

Change(%)

Net Sales

19.10

87.50

-78.17%

Operating Profit (PBDIT) excl Other Income

-10.40

-66.70

84.41%

Interest

10.90

18.80

-42.02%

Exceptional Items

27.50

0.00

Consolidate Net Profit

-77.20

-30.20

-155.63%

Operating Profit Margin (Excl OI)

0.00%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in quarter ended Jun 2012 is -78.17% vs 15.13% in Jun 2011

Consolidated Net Profit

YoY Growth in quarter ended Jun 2012 is -155.63% vs -308.11% in Jun 2011

All Quarterly Results

Annual Results Snapshot (Consolidated) - Sep'23

Sep'23

Sep'22

Change(%)

Net Sales

32.30

40.10

-19.45%

Operating Profit (PBDIT) excl Other Income

-3.00

-6.90

56.52%

Interest

0.20

Exceptional Items

0.00

Consolidate Net Profit

-6.20

-8.70

28.74%

Operating Profit Margin (Excl OI)

-109.20%

-185.30%

7.61%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in year ended Sep 2023 is -19.45% vs -16.46% in Sep 2022

Consolidated Net Profit

YoY Growth in year ended Sep 2023 is 28.74% vs -176.99% in Sep 2022

All Annual Results

Company CV

About Universe Pharmaceuticals, Inc.

Universe Pharmaceuticals, Inc.

Pharmaceuticals & Biotechnology

No Details Available.

Company Coordinates

No Company Details Available

Universe Pharmaceuticals, Inc.

1Day

52 Week

CASH

FII

DII

Promoter

How big is Universe Pharmaceuticals, Inc.?

Watch in Real-Time

What does Universe Pharmaceuticals, Inc. do?

Is Universe Pharmaceuticals, Inc. technically bullish or bearish?

Compare Universe Pharmaceuticals, Inc. with Similar Stocks

MarketsMojo — Loved in India, Now Global

Dashboard

Mojo Parameters

Stock DNA

Total Returns (Price + Dividend)

Risk Adjusted Returns v/s

News

Announcements

Corporate Actions

Quality key factors

Valuation key factors

Technicals key factors

Shareholding Snapshot : Mar 2025

Shareholding Compare (%holding)

Quarterly Results Snapshot (Consolidated) - Jun'12 - YoY

Annual Results Snapshot (Consolidated) - Sep'23

About Universe Pharmaceuticals, Inc.

Company Coordinates